CANCER RESEARCH CAREER ENHANCEMENT (CRCE) The Fred Hutch/University of Washington Cancer Consortium aims to be at the forefront of training the next generation of scientists and clinicians to best position them to lead efforts to eliminate cancer. Education and training has always been a core value and central to our mission, and we propose here to continue to emphasize and enhance our training mission and footprint.
The specific aims for CRCE are (1) to provide exceptional training and support for graduate students and postdoctoral and clinical fellows so that they will be poised to tackle a range of careers in cancer research; (2) to encourage young students to engage in and experience science and to provide exposure and opportunities for those from groups that are underrepresented minorities (URMs) in science; (3) to maximize the success of junior faculty through mentoring and support as they transition to independent scientists; and (4) to support the pipeline of educational and training opportunities of the Consortium. To support our training efforts, we host a large and comprehensive set of T32 grants (n=47), of which 32 have Consortium faculty as mentors, 17 are led by Consortium PIs, and 7 are from NCI. The eight T32s with the strongest cancer focus collectively support 39 trainees/year, and an additional 95 trainees are supported by T32s that include cancer research as a component. Some of these grants have been in continuous existence for more than 4 decades (e.g., Molecular & Cellular Biology, Medical Scientist Training Program, Medical Genetics, Hematology). The caliber of our trainees and their success is illustrated by current active awards of 1 K99 grant, 6 K01 or K22 grants, 10 F32 grants, 2 Jane Coffin Childs Fellowships, 4 Damon Runyon Cancer Research Awards, and 4 Susan G. Komen Fellowships. This Cancer Research Career Enhancement (CRCE) component will serve as a centralized resource that integrates and supports these efforts, encourages the continuum of training and mentoring, and supports continued innovation in our education pipeline.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015704-45
Application #
9853646
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-01-01
Budget End
2020-12-31
Support Year
45
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Poudel, Kumud R; Roh-Johnson, Minna; Su, Allen et al. (2018) Competition between TIAM1 and Membranes Balances Endophilin A3 Activity in Cancer Metastasis. Dev Cell 45:738-752.e6
Holly, Mayumi K; Smith, Jason G (2018) Adenovirus infection of human enteroids reveals interferon sensitivity and preferential infection of goblet cells. J Virol :
Cheng, Heather H (2018) The resounding effect of DNA repair deficiency in prostate cancer. Urol Oncol 36:385-388
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313
Eaton, Keith D; Romine, Perrin E; Goodman, Gary E et al. (2018) Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility. J Thorac Oncol 13:649-659
Graves, Scott S; Parker, Maura H; Stone, Diane et al. (2018) Anti-Inducible Costimulator Monoclonal Antibody Treatment of Canine Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:50-54
Gauthier, Jordan; Turtle, Cameron J (2018) Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr Res Transl Med 66:50-52
Amundsen, Susan K; Smith, Gerald R (2018) The RecB helicase-nuclease tether mediates Chi hotspot control of RecBCD enzyme. Nucleic Acids Res :
Méndez, Eduardo; Rodriguez, Cristina P; Kao, Michael C et al. (2018) A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 24:2740-2748
Buckley, Sarah A; Percival, Mary-Elizabeth; Othus, Megan et al. (2018) A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study. Leuk Lymphoma :1-7

Showing the most recent 10 out of 1267 publications